| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
1 Department of Medicine, Renal Division, Brigham and Women's Hospital, Boston, MA, USA; Department of Medicine, Renal Unit, Massachusetts General Hospital, Boston, MA, USA
2 Department of Anatomy, School of Medicine, Kyungpook National University, Daegu, Korea, Republic of
3 Department of Molecular Biology and Microbiology, Biomolecular Science Center, University of Central Florida, Orlando, FL, USA
4 Department of Medicine, Renal Unit, Massachusetts General Hospital, Boston, MA, USA
5 Department of Medicine, Renal Division, Brigham and Women's Hospital, Boston, MA, USA; Division of Health Sciences and Technology, Harvard-Massachusetts Institute of Technology, Cambridge, MA, USA
* To whom correspondence should be addressed. E-mail: dhentschel{at}partners.org.
Acute renal failure (ARF) is characterized by a very high mortality essentially unchanged over the past 40 years. Simple vertebrate models are needed to improve our understanding of ARF and facilitate the development of novel therapies for this clinical syndrome. Here we demonstrate that gentamicin, a commonly used nephrotoxic antibiotic, causes larval zebrafish to develop ARF characterized by histological and functional changes that mirror aminoglycoside toxicity in higher vertebrates and inability of zebrafish to maintain fluid homeostasis. We developed a novel method to quantitate renal function in larval zebrafish, and demonstrate a decline in glomerular filtration rate after gentamicin exposure. The anti-neoplastic drug cisplatin, whose use in humans is limited by kidney toxicity, also causes typical histological changes and a decline in renal function in larval zebrafish. A specific inhibitor of Omi/HtrA2, a serine protease implicated in cisplatin-induced apoptosis, prevented renal failure and increased survival. This protective effect was confirmed in a mouse model of cisplatin-induced nephrotoxicity. Therefore zebrafish provides a unique model system, amenable to genetic manipulation and drug screening, to explore the pathophysiology of ARF and establish novel therapies with potential use in mammals.
This article has been cited by other articles:
|
|
 |
|
  B. Daroczi, G. Kari, Q. Ren, A. P. Dicker, and U. Rodeck Nuclear factor {kappa}B inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos Mol. Cancer Ther., September 1, 2009; 8(9): 2625 - 2634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Hentschel, M. Mengel, L. Boehme, F. Liebsch, C. Albertin, J. V. Bonventre, H. Haller, and M. Schiffer Rapid screening of glomerular slit diaphragm integrity in larval zebrafish Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1746 - F1750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Daroczi, G. Kari, M. F. McAleer, J. C. Wolf, U. Rodeck, and A. P. Dicker In vivo Radioprotection by the Fullerene Nanoparticle DF-1 as Assessed in a Zebrafish Model Clin. Cancer Res., December 1, 2006; 12(23): 7086 - 7091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bahary Tales from the deep: reeling in renal failure Am J Physiol Renal Physiol, May 1, 2005; 288(5): F921 - F922. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
